152 related articles for article (PubMed ID: 22621180)
1. OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines.
Cohen JL; Dayan SH; Cox SE; Yalamanchili R; Tardie G
Dermatol Surg; 2012 Sep; 38(9):1497-505. PubMed ID: 22621180
[TBL] [Abstract][Full Text] [Related]
2. An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA.
Nettar KD; Yu KC; Bapna S; Boscardin J; Maas CS
Arch Facial Plast Surg; 2011; 13(6):380-6. PubMed ID: 21690460
[TBL] [Abstract][Full Text] [Related]
3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
Solish N; Rivers JK; Humphrey S; Muhn C; Somogyi C; Lei X; Bhogal M; Caulkins C
Dermatol Surg; 2016 Mar; 42(3):410-9. PubMed ID: 26863598
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
7. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA.
Yu KC; Nettar KD; Bapna S; Boscardin WJ; Maas CS
Arch Facial Plast Surg; 2012; 14(3):198-204. PubMed ID: 22183059
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial.
Carruthers A; Bruce S; de Coninck A; Connolly S; Cox SE; Davis PG; Campo A; Lei X; Somogyi C; Lee E; McLean H; Beddingfield F
Dermatol Surg; 2014 Nov; 40(11):1181-90. PubMed ID: 25347451
[TBL] [Abstract][Full Text] [Related]
9. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke.
Dunne JW; Gracies JM; Hayes M; Zeman B; Singer BJ;
Clin Rehabil; 2012 Sep; 26(9):787-97. PubMed ID: 22308557
[TBL] [Abstract][Full Text] [Related]
10. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
11. Safety, Efficacy, and Patient Satisfaction With OnabotulinumtoxinA for the Treatment of Upper Facial Lines in Japanese Subjects.
Kawashima M; Harii K; Horiuchi Y; Seidman E; Lei X; Hopfinger R; Lee E
Dermatol Surg; 2020 Apr; 46(4):483-490. PubMed ID: 31517663
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA treatment of mild glabellar lines in repose.
Carruthers A; Carruthers J; Lei X; Pogoda JM; Eadie N; Brin MF
Dermatol Surg; 2010 Dec; 36 Suppl 4():2168-71. PubMed ID: 21134048
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Patient-Reported Outcomes, and Safety in Male Subjects Treated With OnabotulinumtoxinA for Improvement of Moderate to Severe Horizontal Forehead Lines.
Keaney TC; Cavallini M; Leys C; Rossi A; Drinkwater A; Manson Brown S; Garcia JK; Mao C
Dermatol Surg; 2020 Feb; 46(2):229-239. PubMed ID: 31343446
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA (Botox) in the Treatment of Crow's Feet Lines in Japanese Subjects.
Harii K; Kawashima M; Furuyama N; Lei X; Hopfinger R; Lee E
Aesthetic Plast Surg; 2017 Oct; 41(5):1186-1197. PubMed ID: 28733805
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
Kane MA; Gold MH; Coleman WP; Jones DH; Tanghetti EA; Alster TS; Rohrer TE; Burgess CM; Shamban AT; Finn E
Dermatol Surg; 2015 Nov; 41(11):1310-9. PubMed ID: 26509943
[TBL] [Abstract][Full Text] [Related]
16. Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment.
Carruthers A; Sadick N; Brandt F; Trindade de Almeida AR; Fagien S; Goodman GJ; Raspaldo H; Smith K; Darmody S; Gallagher CJ; Street J; Romagnano L
Dermatol Surg; 2015 Jun; 41(6):693-701. PubMed ID: 25973559
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study.
Won CH; Lee HM; Lee WS; Kang H; Kim BJ; Kim WS; Lee JH; Lee DH; Huh CH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):171-8. PubMed ID: 23301821
[TBL] [Abstract][Full Text] [Related]
18. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
[TBL] [Abstract][Full Text] [Related]
19. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
Kuo HC
Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.
Ascher B; Rzany BJ; Grover R
Dermatol Surg; 2009 Oct; 35(10):1478-86. PubMed ID: 19686365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
